刺五加注射液联合氟西汀治疗老年痴呆抑郁症57例及安全性评价

Acanthopanax Injection Combined with Fluoxetine for Treating Depression in Alzheimer's Disease in 57 Cases and Its Safety Evaluation

目的探讨刺五加注射液联合氟西汀治疗老年痴呆抑郁症的临床疗效并评价其安全性。方法选取合并抑郁症的老年痴呆患者114例,随机分为对照组和观察组,各57例。对照组患者给予氟西汀治疗,观察组患者在对照组基础上给予静脉滴注刺五加注射液治疗。比较两组患者抑郁疗效、帕金森氏病综合评分量表(UPDRS)评分及不良反应发生情况。结果治疗后,观察组抑郁治疗总有效率显著高于对照组(P<0.05);两组患者UPDRS评分较治疗前均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);两组患者均出现轻微头痛、心悸、嗜睡等症状,但无严重不良反应发生。结论刺五加注射液联合氟西汀治疗老年痴呆合并抑郁症疗效显著,能有效改善患者的运动症状和生活质量,安全可靠,优于单用氟西汀治疗,值得临床推广。

Objective To investigate the clinical efficacy of Acanthopanax Injection combined with fluoxetine in the treatment of depres-sion in alzheimer's disease and to evaluate its safety. Methods 114 cases of alzheimer's patients with depression were randomly divid-ed into the control group and the observation group,57 cases in each group. The control group received fluoxetine treatment,the obser-vation group was given intravenous Acanthopanax Injection on the basis of the control group. The efficacy in patients with depression, UPDRS scores and adverse events were compared. Results After treatment,the effective treatment of depression of the observation group was significantly higher than the control group ( P < 0. 05);the UPDRS scores of the two groups were significantly lower than before treatment ( P < 0. 05),and the UPDRS score of the observation group was significantly lower than the control group ( P < 0. 05);all patients showed mild headache,palpitations,lethargy and other symptoms,but no serious adverse events. Conclusion Acanthopanax Injec-tion combined with fluoxetine treatment of depression in alzheimer's disease has significant effect,can effectively improve symptoms and quality of life of patients;it is safe,reliable,and superior to using fluoxetine alone,which is worthy of clinical promotion.